Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non‐Hodgkin’s lymphoma6
Authors:
- Michinori OguraMOMichinori Ogura
- for the Japanese Bendamustine Lymphoma Study GroupFGfor the Japanese Bendamustine Lymphoma Study Group
Open Access
- 30 May 2011
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 102 (9) , 1687-1692
Abstract
Although bendamustine plus rituximab has demonstrated efficacy in indolent B cell non‐Hodgkin’s lymphoma (B‐NHL), data for this combination in aggressive B‐NHL are extremely limited. The present dose‐escalation study evaluated the safety, efficacy, and pharmacokinetics of bendamustine hydrochloride in combination with rituximab in patients with relapsed/refractory, CD20‐positive, aggressive B‐NHL. Patients received rituximab 375 mg/m2, i.v., on Day 1 and bendamustine at either 90 (Cohort 1) or 120 mg/m2 (Cohort 2), i.v., on Days 2 and 3 of a 21‐day cycle. The primary endpoint was the proportion of patients experiencing dose‐limiting toxicity (DLT). Secondary endpoints were adverse events (AE), the overall response rate (ORR), and pharmacokinetic parameters. Nine patients received rituximab plus bendamustine: three in Cohort 1 and six in Cohort 2. Histologies included diffuse large B cell lymphoma (n = 5), mantle cell lymphoma (n = 2), and transformed lymphoma (n = 2). No DLT was observed at either dose level. Grade 3/4 hematologic AE included lymphocytopenia, leukocytopenia, and neutropenia (n = 9 each; 100%), and thrombocytopenia (n = 2; 22%). No Grade 3/4 gastrointestinal AE were reported. The ORR was 33% (one partial response) in Cohort 1 and 100% (five complete and one partial response) in Cohort 2. The maximum drug concentration and area under the blood concentration–time curve for bendamustine increased dose dependently, with time to maximum blood concentration = 1.0 h in both cohorts; these pharmacokinetic data were similar to those reported previously for single‐agent bendamustine in patients with indolent B‐NHL. In conclusion, bendamustine 120 mg/m2 plus rituximab 375 mg/m2 was feasible and generally well tolerated, with promising efficacy in relapsed or refractory aggressive B‐NHL. (Cancer Sci 2011; 102: 1687–1692)Keywords
This publication has 20 references indexed in Scilit:
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphomaCancer Science, 2010
- Multicenter phase II study of bendamustine for relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphomaCancer Science, 2010
- Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphomaCancer Chemotherapy and Pharmacology, 2010
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating AgentsClinical Cancer Research, 2008
- A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumoursBritish Journal of Cancer, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)Journal of Cancer Research and Clinical Oncology, 2006
- Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995